Biotech Values

[oc631]

Manifestation of liver toxicity is always a bad thing for a drug that treats liver disease, but in this case it’s even worse than usual. That’s because ACHN was hoping to position ACH-1625 as a best-in-class PI for patents with HCV/HIV co-infection.

I'm unable to pull up a CC replay just yet. The last thing ACHN wants is the FDA looking closer at sovaprevir data. This drug has a questionable safety profile, people are leaving the company, they are raising money when they don't have to, they are running unusually small combo studies, etc. For me the writing's on the wall. The glass half full crowd will buy the dip on news that the combo study is still going and wind up with an empty glass.